Suggested remit: To appraise the clinical and cost effectiveness of sotatercept within its marketing authorisation for treating pulmonary arterial hypertension.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6163

Email enquiries


Key events during the development of the guidance:

Date Update
12 March 2024 Please note that following a call between NICE and the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early June 2024 when we will write to you about how you can get involved.
27 October 2023 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations, and further details regarding timings and how you can get involved will be available in due course.
19 September 2023 (10:00) Scoping workshop
27 July 2023 - 24 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6163
13 October 2022 In progress. DHSC referral received
03 August 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual